PDGene


	The Michael J. Fox Foundation for Parkinson's Research

		Research
		News & Events
		Funding Programs
		About

	PD Online Research

	Alzheimer Research Forum

		Current Papers
		ARF Recommends
		Research News

Gene overview of all published PD-association studies for UCHL1

Gene:

UCHL1 (Uch-L1; PARK5; PGP9.5)

View on AlzGene

Protein:

ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)

Chromosome:

4 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 29 June 2010

1. Case-Control Studies (by ethnic group)
				PD Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Carmine, 2007	Sweden	CL	1 (detail)	296 (-)	C	60 (-)	68 (-)	235 (-)	57 (-)	Positive	Submit comment
Elbaz, 2003	France	CO	1 (detail)	209 (43%)	C	65 (35-75)	68 (37-75)	488 (41%)	68 (36-79)	Positive	Submit comment
Facheris, 2005	Overlaps with Maraganore, 1999	CL	1 (detail)	70 (-)	C	-	-	70 (-)	-	n.a.	Submit comment
Fung, 2006	USA (NINDS)	CL	1 (detail)	267 (-)	C	-	-	270 (-)	68 (55-88)	Negative	Submit comment
Healy, 2006	UK, Ireland	CL	3 (detail)	1536 (-)	M	58.3 (-)	-	1487 (-)	56.1 (-)	Negative	Submit comment
Hutter, 2007	USA	CL	1 (detail)	1757 (32%)	C	58.7 + 11.6 (-)	68 + 10.5 (-)	2016 (63%)	67.4 + 18.2 (-)	Negative	Submit comment
Levecque, 2001	France	CL	1 (detail)	114 (53%)	C	58.7 + 11.3 (-)	66.5 + 10.6 (-)	93 (51%)	66.9 + 9.5 (-)	Negative	Submit comment
Maraganore, 1999	USA	CL	1 (detail)	139 (35%)	C	62 (31-82)	69 (39-91)	113 (65%)	72 (37-90)	Positive	Submit comment
Maraganore, 2003	Overlaps with Maraganore, 1999	CL	1 (detail)	298 (38%)	C	63.4 (31-85)	69.8 (33-99)	185 (63%)	72.1 (37-94)	n.a.	Submit comment
McCulloch, 2008	Overlaps with Hutter, 2007 (USA-Washington)	CL	1 (detail)	391 (26%)	C	-	67.3 (32-95)	293 (58%)	67.3 (30-93)	n.a.	Submit comment
McCulloch, 2008	Overlaps with Hutter, 2007 (USA-Oregon)	CL	1 (detail)	172 (38%)	C	-	65.9 (39-87)	96 (55%)	67.8 (21-83)	n.a.	Submit comment
McCulloch, 2008	Overlaps with Hutter, 2007 (USA-NY)	CL	1 (detail)	253 (35%)	C	-	68.1 (40-95)	214 (66%)	64.6 (34-94)	n.a.	Submit comment
McCulloch, 2008	Overlaps with Hutter, 2007 (USA-Georgia)	CL	1 (detail)	116 (37%)	C	-	67.3 (40-97)	61 (67%)	68.5 (51-84)	n.a.	Submit comment
Mellick, 2000	Australia	CL	1 (detail)	142 (51%)	C	59 + 11 (32-83)	66 + 11 (37-85)	142 (51%)	66 + 10 (39-86)	Negative	Submit comment
Savettieri, 2001	Italy	CL	1 (detail)	169 (41%)	C	59 (37-84)	67 (43-87)	165 (55%)	73 (60-96)	Negative	Submit comment
Sutherland, 2009	Australia	CL	3 (detail)	331 (51%)	C	60.1 + 10.6 (-)	70.3 + 8.7 (-)	296 (51%)	70.5 + 8.9 (-)	Trend	Submit comment
Wintermeyer, 2000	Germany	CL	1 (detail)	229 (44%)	C	-	66.3 + 10.8 (-)	200 (48%)	72 + 4.3 (-)	Positive	Submit comment
Zhang, 2000	USA	CL	1 (detail)	153 (-)	M	60.6 + 8.8 (-)	-	142 (-)	72.5 (-)	Negative	Submit comment
Asian
Mizuta, 2006	Overlaps with Mizuta, 2008	CL	4 (detail)	882 (56%)	C	57.4 + 10.9 (-)	64.9 + 9.8 (-)	938 (48%)	45.3 + 16.3 (-)	Negative	Submit comment
Mizuta, 2008	Japan	CL	1 (detail)	882 (56%)	C	57.4 + 10.9 (-)	64.9 + 9.8 (-)	938 (48%)	45.6 + 16.3 (-)	Negative	Submit comment
Momose, 2002	Overlaps with Mizuta, 2008	CL	1 (detail)	232 (51%)	C	54.1 + 10.5 (24-80)	-	249 (49%)	-	n.a.	Submit comment
Satoh, 2001	Japan	CL	1 (detail)	74 (62%)	C	-	69 + 8.8 (46-86)	155 (49%)	66.4 + 11.8 (40-88)	Positive	Submit comment
Tan, 2006	Overlaps with Tan-Singapore (Tan), 2009	CL	1 (detail)	335 (44%)	C	61 + 11 (-)	65 + 10 (30-89)	341 (47%)	61 + 11 (26-93)	n.a.	Submit comment
Tan, 2009	China (Lu)	CL	1 (detail)	608 (-)	C	-	-	386 (-)	-	Negative	Submit comment
Tan, 2009	China (Robin)	CL	1 (detail)	252 (-)	C	-	-	231 (-)	-	Negative	Submit comment
Tan, 2009	China (Peng)	CL	1 (detail)	600 (-)	C	-	-	334 (-)	-	Negative	Submit comment
Tan, 2009	Singapore (Tan)	CL	1 (detail)	441 (-)	C	-	-	449 (-)	-	Trend	Submit comment
Tan, 2009	Overlaps with Wu, 2010	CL	1 (detail)	242 (-)	C	-	-	363 (-)	-	n.a.	Submit comment
Toda, 2003	Overlaps with Mizuta, 2008	CL	1 (detail)	232 (51%)	C	54.1 + 10.5 (24-80)	-	249 (49%)	-	n.a.	Submit comment
Wang, 2002	China	CL	1 (detail)	160 (44%)	C	58.8 + 12.6 (30-82)	66.8 + 11.2 (34-86)	160 (44%)	65.9 + 12.8 (34-86)	Positive	Submit comment
Wu, 2010	Taiwan	CL	1 (detail)	517 (44%)	C	62.7 + 11.3 (19-86)	-	518 (48%)	59 + 13.3 (28-94)	Positive
Zhang, 2000	Japan	CL	1 (detail)	160 (-)	C	55.4 + 10.7 (-)	-	160 (-)	58.1 (-)	Positive	Submit comment
Zhang, 2008	Overlaps with Tan-China (Peng), 2009	CL	1 (detail)	600 (41%)	C	55.9 + 11.6 (20-85)	-	334 (46%)	53.5 + 13.7 (24-91)	n.a.	Submit comment

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Facheris, 2005	Overlaps with Maraganore, 1999	1 (detail)		427 (-)	C	-	-	427 (-)	-	Positive	Submit comment

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis -> "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.